ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
CAMBRIDGE, Mass., April 06, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 4:20 p.m. ET in New York City.
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]
